21Vianet Group Inc (NASDAQ:VNET) was falling Friday after missing analysts’ estimates for earnings in the first quarter. For the first quarter 21Vianet reported earnings of 8 cents a share, missing the Capital IQ Consensus Estimate of 10 cents a share by 2 cents. Revenue grew 34.4% from the year-ago quarter to $94.3 million. Analysts expected revenue of $93.53 million for the quarter. 21Vianet Group Inc (NASDAQ:VNET) net profit margin is -2.50% and weekly performance is 0.08%. On last trading day company shares ended up $25.87. Analysts mean target price for the company is $32.33. 21Vianet Group Inc (NASDAQ:VNET) distance from 50-day simple moving average (SMA50) is -1.48%.
On May 5, 2014, Spherix Inc (NASDAQ:SPEX), an intellectual property development company committed to the fostering and monetization of intellectual property, commenced litigation against Juniper Networks, Inc., in the United States District Court for the District of Delaware, alleging that the Sunnyvale, California based company infringes five patents owned by Spherix. Spherix Inc (NASDAQ:SPEX) shares advanced 8.63% in last trading session and ended the day on $1.51. SPEX return on assets is -101.00%. Spherix Inc (NASDAQ:SPEX) quarterly performance is -69.12%.
On May 20, 2014, Prosensa Holding NV (NASDAQ:RNA) reported financial results for the first quarter ending March 31, 2014 and provided an update on the next steps for its exon-skipping platform for the treatment of Duchenne Muscular Dystrophy (DMD). Prosensa Holding NV (NASDAQ:RNA) shares moved up 27.04% in last trading session and was closed at $8.41, while trading in range of $7.65 – $8.96. Prosensa Holding NV (NASDAQ:RNA) year to date (YTD) performance is 80.09%.
On May 22, 2014, Atossa Genetics Inc (NASDAQ:ATOS) announced that its Board of Directors has approved the adoption of a stockholder rights agreement. The stockholder rights agreement is designed to deter coercive, unfair, or inadequate takeovers and other abusive tactics that might be used in an attempt to gain control of Atossa without paying all stockholders a fair price for their shares. The stockholder rights agreement will not prevent takeovers at a full and fair price, but is designed to deter coercive takeover tactics and to encourage anyone attempting to acquire Atossa to first negotiate with the Board of Directors. Atossa Genetics Inc (NASDAQ:ATOS) ended the last trading day at $1.55. Company weekly volatility is calculated as 27.62% and price to cash ratio as 6.02. Atossa Genetics Inc (NASDAQ:ATOS) showed a positive weekly performance of 30.25%.